Pompe disease can be treated with systemic recombinant human GAA (rhGAA) enzyme replacement therapy (ERT), but the current standard of care exhibits poor uptake in skeletal muscles, limiting its clinical efficacy. The gene discussed is GAA; the disease is Glycogen storage disease due to acid maltase deficiency.